Cisgender gay and bisexual men, transgender women, and transgender men remain at higher risk for HIV acquisition.

Gilead Sciences, Inc. GILD recently announced additional efficacy, safety and demographic data from its late-stage study on lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, for the ...

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...

"Madagascar’s HIV epidemic is being fueled by gaps in prevention and glaring inequalities, which urgently need to be ...

Health NGO, Right to Care, highlights the urgent need for circumcision among boys aged 15 and older in KwaZulu-Natal to ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Marine, not her real name, was considering surgery to deal with intense pain. Three doctors refused to see her before a ...

In the complex landscape of chronic health conditions, living with HIV while recovering from a stroke presents a unique set ...

Namibia has made significant strides in stemming the spread of HIV and AIDS through education and prevention. However, for people like Anna Engomba, the arrival of new, life-saving medication cannot ...

The second of two pivotal studies of a six-monthly HIV prevention injection containing the antiretroviral drug lenacapavir ...

Clarence Peeples is part of a small club in the HIV community. He is using his experiences to help fight the virus among ...

Two posters compared health care resource utilization (HCRU) and financial burdens of people living with HIV with a non-HIV ...